Privately owned drug discovery company Nimbus Therapeutics on Tuesday announced that it expanded its research collaboration with Eli Lilly (LLY) to develop an oral obesity therapy in a deal worth up ...

Us Weekly has affiliate partnerships. We receive compensation when you click on a link and make a purchase. Learn more! Lilly Pulitzer is kicking off 2026 the only way it knows how — with color, cheer ...

This year's Rose Bowl was so uncompetitive that fans paid more attention to the commercials than the actual game. To be fair, Indiana squashed Alabama in the quarterfinals of the College Football ...

Dec 29 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab and Eli Lilly (LLY.N), opens new tab are lowering prices of their top-selling obesity drugs Wegovy and Mounjaro in China, according to the ...

Eli Lilly (LLY) achieved 54% year-over-year revenue growth to $17.6B in Q3. Tirzepatide is projected as the top-selling drug by 2030. Lilly raised its quarterly dividend 15% to $1.73 per share. The ...

Eli Lilly stock delivered ~40% since my initial bullish article. Novo pressures with oral Semaglutide and CagriSema, but that is just a timing issue before Retatrutide + Orforglipron take the stage.